

 **Allergan**
Q3 18
RESULTS

NET REVENUE \$3.9 BILLION

**PERFORMANCE NET
INCOME PER SHARE*** \$4.25

*GAAP Loss Per Share \$0.11

ALLERGAN **RAISED FULL-YEAR
2018 GUIDANCE** FOR NET
REVENUE AND NON-GAAP
PERFORMANCE NET INCOME
PER SHARE

R&D PIPELINE ADVANCEMENTS
INCLUDE CARIPRAZINE
AND UBROGEPANT

PRO-FORMA **DEBT
REDUCTION OF
\$750 MILLION****

REVENUE DRIVEN BY GROWTH IN TOP PROMOTED PRODUCTS:



* Performance net income per share refers to non-GAAP metrics. Please refer to the GAAP to non-GAAP tables in October 30, 2018 Press Release on Allergan.com for a reconciliation of our non-GAAP results

** \$750M represents the portion of the \$1.76B debt repurchase in Q3 2018 that is not expected to be refinanced